推荐！钱塘新区杭州医药港招商宣传片

杭州是浙江省的省会，市域面积1.68万平方公里，人口1036万。杭州经济已位居中国十大城市之列，经济实力雄厚。2019年，杭州实现地区生产总值15373亿元，实现财政收入3650亿元。2019年4月，浙江省人民政府批复设立杭州钱塘新区，空间范围包括杭州大江东产业集聚区和杭州经济技术开发区。新区实行“一个平台、一个主体、一套班子、多块牌子”的管理体制架构，拥有杭州经济技术开发区、临江高新技术开发区3块国家级牌子，托管下沙、白杨、河庄、义蓬、新湾、临江、前进7个街道，常住人口106万，规划控制总面积531.7平方千米。

杭州医药港位于杭州钱塘新区，距杭州火车东站10公里，距杭州萧山国际机场15公里，50分钟直达上海，共有七条高速公路形成长三角城市“1小时”交通圈。杭州医药港面积3.5平方公里，产值规模350亿元，占杭州市比重达50%，是浙江省和杭州市生物医药产业的核心区，重点围绕生物技术药物、生物医学工程、高端医疗器械及医疗大数据四大领域进行产业培育和招引。截至2019年底，杭州医药港已集聚各类生物医药企业1000家以上，其中全球十强药企已落户7家，包括辉瑞、默沙东、礼来、吉利德、拜耳、雅培、强生等。杭州医药港将以打造国内领先、国际一流的生物医药研发创新高地为目标，到2025年，力争实现生物医药产业主营业务收入达1000亿元，累计企业4000家，规上企业数量150家,R&D比重达12%，集聚市521以上高层次人才200名。

Hangzhou, the provincial capital of Zhejiang Province, has an area of 16,800 square kilometers and a population of 10.36 million. Hangzhou’s economy ranks among the top ten cities in China, and its economic strength is strong. In 2019, Hangzhou achieved a GDP of 1,537.3 billion yuan and a revenue of 365 billion yuan. In April 2019, Zhejiang Provincial Government approved the establishment of Hangzhou Qiantang New Area which covers Hangzhou Dajiangdong Industrial Cluster and Hangzhou Economic and Technological Development Area. The New Area implements the management system framework of “One Platform, One Project, One set of Team and Multiple Brands”. It holds three national-level brands, namely Hangzhou Economic and Technological Development Area, Hangzhou comprehensive Bonded Zone and Linjiang High-tech Industrial Development Zone. It holds Xisha, Baiyang, Hezhuang, Yipeng, Xinwan, Linjiang,and Qianjing substreet. It has a permanent population of 1.06 million and the total planned area is 531.7 square kilometers.

Hangzhou Biopharma Town (HBT) is located in Hangzhou Qiantang New Area, 10km away from Hangzhou Eastern Railway Station, 15km from Xiaoshan International Airport, and 50 minutes to Shanghai by high-speed railway. There are seven expressways forming a “1 hour” traffic circle to the Yangtze River Delta cities. HBT Covers an area of 3.5 square kilometers, with biomedicine industry output value reaching 35 billion yuan, which accounts for 50% of Hangzhou’s, thus becomes the core area for Zhejiang and Hangzhou to develop biomedical industry, focusing on biotechnology drugs, biomedical engineering, high-end medical apparatus and medical big data for industry cultivation and recruitment. By the end of 2019, HBT had gathered over 1000 bio-pharmaceutical enterprises, and seven of the top ten pharmaceutical companies in the world had settled here, including Pfizer, Merck, Eli Lilly, Gilead, Bayer, Abbott and Johnson & Johnson. HBT will aim to build a domestic leading and international first-class biomedical R&D and innovation highland. By 2025, HBT strives to achieve a revenue of 100 billion yuan in the main business of the biopharmaceutical industry, to gather 4,000 enterprises including 150 regulated enterprises, to reach R & D ratio of 12%, and to gather 200 municipal, provincial and national high-level talents.